Literature DB >> 33165978

Device related thrombus after left atrial appendage closure: State of the art.

Jiangtao Yu1, Yuan Bai2, Li-Sheng Jiang3.   

Abstract

Atrial fibrillation (AF), the most common arrhythmia, is a major cause of stroke and systemic embolism. Patients with AF are at higher risk of stroke with the left atrial appendage (LAA) being the most common site for thrombus formation. Although oral anticoagulation (OAC) remains the standard of care for stroke prevention in AF patients, there are still several limitations, including increased risk of bleeding and noncompliance. LAA closure (LAAC) has been found to be non-inferior to OAC in preventing all-cause strokes and systemic embolisms in randomized clinical trials, and is increasingly performed for stroke prevention in patients with nonvalvular AF (NVAF). However, device-related thrombus (DRT) after LAAC and a potentially increased risk of stroke related to DRT were observed in several registered studies, and attract wide concern. This review provides a comprehensive update on the incidence, mechanism, risk factors, prevention, diagnosis, and treatment of DRT after LAAC in patients with NVAF.
© 2020 Wiley Periodicals LLC.

Entities:  

Mesh:

Year:  2020        PMID: 33165978     DOI: 10.1111/pace.14122

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  2 in total

1.  Endothelium-Mimicking Nanomatrix Coating to Enhance Endothelialization after Left Atrial Appendage Closure Device Implantation.

Authors:  Patrick T J Hwang; Jennifer A Sherwood; Reid C Millican; Pratheek S Bobba; Tyler O Lynd; Joseph N Garner; Brigitta C Brott; Dongming Hou; Ho-Wook Jun
Journal:  ACS Appl Bio Mater       Date:  2021-06-01

2.  Left atrial appendage closure in nonvalvular atrial fibrillation patients with percutaneous coronary intervention.

Authors:  Yunan Yu; Jing Xu; Liang Wang; Zi Ye; Zhisong Chen; Fadong Chen
Journal:  BMC Cardiovasc Disord       Date:  2022-10-03       Impact factor: 2.174

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.